GöttinGen 7.- 9. Februar - Programm - Jahrestagung des Deutschen Pankreasclubs eV
←
→
Transkription von Seiteninhalten
Wenn Ihr Browser die Seite nicht korrekt rendert, bitte, lesen Sie den Inhalt der Seite unten
Programm © fotobeam.de l Fotolia.com DPC 39. Jahrestagung des Deutschen Pankreasclubs e. V. 7.– 9. Februar Göttingen www.dpc-kongress.de
WIR ENGAGIEREN UNS FÜR SCHWERWIEGENDE UND SELTENE ERKRANKUNGEN MIT DER FORSCHUNGSKOMPETENZ ANTISENSE-TECHNOLOGIE 2 DE-AKCEA-0009-V01-2018-10
INHALTSVERZEICHNIS Organisation und Impressum . ............................................................................................... 4 Grußwort der Tagungsleitung ................................................................................................ 5 Workshops I Donnerstag, 7. Februar ................................................................................... 6 Wissenschaftliches Programm Donnerstag, 7. Februar ................................................................................................. 7 Freitag, 8. Februar ......................................................................................................... 9 Samstag, 9. Februar . ..................................................................................................... 14 Posterpräsentationen Donnerstag, 7. Februar ................................................................................................. 17 Freitag, 8. Februar ......................................................................................................... 22 Abend- und Rahmenprogramm ............................................................................................. 27 Industriegestützte Sessions.................................................................................................... 28 Sponsoren und Medienkooperation ..................................................................................... 32 Aussteller ................................................................................................................................ 34 Raum- und Ausstellerplan ...................................................................................................... 35 Allgemeine Informationen ..................................................................................................... 36 Index Referenten, Autoren und Vorsitzende . ....................................................................... 37 3
ORGANISATION UND IMPRESSUM Tagungsort und Termin Tagungs- und Veranstaltungshaus Alte Mensa Göttingen Wilhelmsplatz 3 I 37073 Göttingen 7.–9. Februar 2019 Tagungshomepage www.dpc-kongress.de Veranstalter Deutscher Pankreasclub e. V. www.pankreasclub.de Wissenschaftliche Leitung PD Dr. Dr. med. Albrecht Neeße Klinik für Gastroenterologie und gastrointestinale Onkologie Universitätsmedizin Göttingen Tagungsorganisation Conventus Congressmanagement & Marketing GmbH Ariane Kärger/Carolin Hofmann Carl-Pulfrich-Straße 1 I 07745 Jena Tel. +49 3641 31 16-325/-378 dpc@conventus.de I www.conventus.de Programmerstellung Satz krea.tif-studio UG (haftungsbeschränkt) Druck printworld.com GmbH Auflage 300 Redaktionsschluss 18. Januar 2019 4
GRUSSWORT DER TAGUNGSLEITUNG Liebe Kolleginnen und Kollegen, ich freue mich, Sie im Jahr 2019 zur 39. Jahrestagung des Deutschen Pankreasclubs e. V. nach Göttingen, in die Stadt, die Wissen schafft, einzuladen. Das Leitbild 2019 „Pankreatologie im Zeitalter der Viszeralmedizin: Translation und Vernetzung“ soll als Basis für den interdisziplinären wissenschaftlichen und klinischen Austausch dienen. Nationale und internationale renommierte Experten werden Sie aktuell und praxisnah auf den neuesten Stand der Pankreasforschung und klinischen Versorgung bringen. Zusätzlich bieten wir auch 2019 wieder die Möglichkeit, sich am Donnerstagvormittag in klinisch und translational orientierten Veranstaltungen und Workshops praxisrelevantes Wissen anzueignen. Ich freue mich auf eine lebhafte Tagung, viele inspirierende Akzente und facettenreiche Diskussionen. Herzliche Grüße, Ihr Albrecht Neeße © di s p l ay i nte r may a l f o to lia.c o m 5
WORKSHOPS I DONNERSTAG, 7. FEBRUAR WORKSHOPS I THURSDAY, 7 FEBRUARY All workshops will take place at the University Hospital Göttingen (Robert-Koch-Straße 40). 09:30–12:30 Workshop 1 l Diagnostische und interventionelle Sonographie in der Pankreatologie (B-Bild, CEUS, EUS, EUS-FNA/FNB) mit Live Demo Room Department of Gastroenterology and Gastrointestinal Oncology B-Bild Sonographie der Pankreatologie V. Keim (Leipzig) CEUS G. Petzold (Göttingen) Endosonographie der Pankreatologie A. Arlt (Kiel) Live Demo S. Kunsch (Göttingen) 09:30–12:30 Workshop 2 l Syngenic orthotopic PDAC cell transplantation Room Laboratories Gastroenterology and Gastrointestinal Oncology Theory and Hands-on Training E. Hessmann (Göttingen) 09:30–12:30 Workshop 3 l High-resolution ultrasound and preclinical trial design using orthotopic and genetically engineered model systems Room Laboratories Gastroenterology and Gastrointestinal Oncology Theory and Hands-on Training R. Goetze (Göttingen) 08:30–12:30 Workshop 4 l Präparierkurs Pankreaskopfresektion Room Anatomy of the University Hospital Göttingen Hands-on Training J. Gaedcke (Göttingen) 10:30–12:30 PASS 1-2 Trials Meeting Room Lecture Theater 552 6
WISSENSCHAFTLICHES PROGRAMM I DONNERSTAG, 7. FEBRUAR SCIENTIFIC PROGRAMME I THURSDAY, 7 FEBRUARY 13:30–14:00 Welcome session Room Adam-von-Trott-Saal Welcome note of the conference chair A. Neeße (Göttingen) Welcome note of the DGIM secretary general U. R. Fölsch (Kiel) 14:00–15:30 Session 1 I Clinical and translational pancreatology Room Adam-von-Trott-Saal Chairs U. Wittel (Freiburg), I. E. Demir (Munich) 14:00 Keynote I Walter Halangk memorial lecture The German Pancreas Club will honor the memory of Walter Halangk (longtime secretary of the DPC) with a Walter Halangk memorial lecture by J. Mayerle (Munich) 14:18 Neoadjuvant treatment for locally advanced pancreatic cancer – prognostic factors of survival U. Klaiber, E. S. Schnaidt, U. Heger, M. Sachsenmaier, U. Hinz, O. Strobel M. W. Büchler, T. Hackert (Heidelberg) 14:26 Targeting DNA damage response by establishing synergistic therapeutic routes in DDR deficient pancreatic cancer L. Perkhofer, J. Gout, M. Morawe, F. Arnold, P.-O. Frappart, A. Kleger (Ulm) 14:34 Theranostic targeting of pancreatic cancer cells using CD44 variant 6-specific aptamers J. Peterhansl, U. M. Mahajan, E. Osterode, K. Lauber, Qi. Li, I. Regel J. Mayerle (Munich) 14:42 Keynote I Metabolism in pancreatic diseases – To fast or not to fast! H. Algül (Munich) 15:00 Prognostic impact of tumor-infiltrating leukocytes on survival of patients with primary resected pancreatic cancer R. C. Miksch, M. Weniger, S. Ormanns, J. Werner, A. V. Bazhin J. G. D’Haese (Munich) 15:08 P90-RSK as a synthetic lethal target in pancreatic cancer – molecular characterisation and therapeutic inhibition J. Riedel (Halle a. d. Saale), N. Milosevic (Gießen), J. von Kries M. Nazare (Berlin), H. Griesmann, P. Michl (Halle a. d. Saale) 15:16 Locally advanced and borderline-resectable pancreatic adenocarcinoma: neoadjuvant FOLFIRINOX as part of a multimodal strategy with curative intention S. Acciuffi, J. Omari, R. Drewes, D. Jechorek, R. Croner, H. Ptok (Magdeburg) 7
WISSENSCHAFTLICHES PROGRAMM I DONNERSTAG, 7. FEBRUAR SCIENTIFIC PROGRAMME I THURSDAY, 7 FEBRUARY 15:45–17:15 Poster sessions 1–3 (please see pages 17–21) 17:30–19:00 Session 2 I Pancreatitis and pancreatic cancer – clinical and basic science Room Adam-von-Trott-Saal Chairs R. Jaster (Rostock), G. von Figura (Munich) 17:30 Keynote I Autoimmune pancreatitis and the UEG guideline effort J. Rosendahl 17:48 Clinical significance of immunosuppressive therapy with tacrolimus in IgG4-related autoimmune pancreatitis – our experience in a cohort of 71 patients A. Kahraman, M. Büchter, G. Gerken (Essen) 17:56 Foxp3+/CD25+ regulatory T cells influence the T-cell response and systemic inflammation in a mouse model of acute pancreatitis J. Glaubitz, A. Wilden, C. van den Brandt, F. U. Weiß (Greifswald) J. Mayerle (Munich), M. M. Lerch, M. Sendler (Greifswald) 18:04 The Axon Guidance Receptor ROBO3 mediated transcriptional regulation links to pancreatic cancer plasticity N. Krebs, S. Önder, X. Xu, J. M. Güntner, M. Tu, V. Ellenrieder S. K. Singh (Göttingen) 18:12 PPDPF impacts human pancreatic progenitor cell formation M. Breunig, M. Hohwieler, N. Zhang (Ulm), J. Glöckner (Tübingen) T. Seufferlein (Ulm), S. Liebau (Tübingen), A. Kleger (Ulm) 18:20 Oncogenic network analysis of ALDH1A3-positive pancreatic ductal adenocarcinoma M. Shi, J. Cao, J. Akkan, N. Maeritz, G. O. Ceyhan, H. Friess (Munich) C. Michalski, J. Kleeff (Halle a. d. Saale), B. Kong (Munich) 18:28 Epigenetic modifications distinguish between the classical and basal pancreatic cancer subtype S. Pichlmeier, A. Kirmayr, S. Benitz, U. M. Mahajan, L. Fahr (Munich) C. Michalski, J. Kleeff (Halle a. d. Saale), J. G. D’Haese, J. Mayerle I. Regel (Munich) 18:36 Keynote I Why surgical treatment for chronic pancreatitis patients is so important G. O. Ceyhan (Istanbul/TR) 19:30–21:30 Get together (please see page 27) 8
WISSENSCHAFTLICHES PROGRAMM I FREITAG, 8. FEBRUAR SCIENTIFIC PROGRAMME I FRIDAY, 8 FEBRUARY 08:30–10:00 Session 3 I Pancreatic surgery Room Adam-von-Trott-Saal Chairs J. Kleeff (Halle a. d. Saale), J. Gaedcke (Göttingen) 08:30 Keynote I Opportunities and limits of minimally invasive pancreatic surgery T. Keck (Lübeck) 08:48 Long-term overall survival and prognostic factors after pancreatoduodenectomy for ampullary cancer – analysis of a large multicenter cohort of more than 200 patients L. Bolm, K. Ohrner (Lübeck), F. Rückert (Mannheim) B. M. Rau (Neustadt i. d. Oberpfalz), E. Petrova, D. Bausch (Lübeck) J. Weitz (Dresden), T. Keck, U. Wellner (Lübeck), M. Distler (Dresden) 08:56 An R0-resectable, genetically engineered mouse model of pancreatic cancer mimics the response to neoadjuvant chemotherapy in human PDAC C. Mota-Reyes (Munich), B. Mundt, J. Brooks (Hannover), B. Konukiewitz A. Muckenhuber, S. Teller, W. Weichert (Munich), F. Kühnel (Hannover) H. Friess, G. O. Ceyhan, I. E. Demir (Munich) 09:04 Volume outcome relationship in pancreatic surgery – effects of hospital and surgeon volume on mortality and postoperative pancreatic fistula S. Acciuffi, H. Ptok (Magdeburg), I. Gastinger (Cottbus) R. Croner (Magdeburg), H. Dralle (Essen) 09:12 Keynote I Career options for young surgeons – Clinic, science or both? C. Michalski (Halle a. d. Saale) 09:30 Trans-parenchymatous sutures cause substantial and persistent inflammation in mouse pancreas C. Kühlbrey, A. Zabadne, U. Wittel (Freiburg) 09:38 Patterns of recurrence after resection of pancreatic ductal adenocarcinoma in the ESPAC-4 Trial J. Neoptolemos, T. Hackert, C. Tjaden (Heidelberg), R. Jones, E. Psarelli R. Jackson, P. Ghaneh, C. Halloran, D. Palmer (Liverpool/GB), O. Strobel M. Buchler (Heidelberg) 09:46 Activated stroma index in neoadjuvantly treated patients with pancreatic ductal adenocarcinoma A. Martens, U. Heger, B. Walter, H. Sun, S. Roth (Heidelberg) C. Michalski (Halle a. d. Saale), M. W. Büchler, T. Hackert (Heidelberg) 9
WISSENSCHAFTLICHES PROGRAMM I FREITAG, 8. FEBRUAR SCIENTIFIC PROGRAMME I FRIDAY, 8 FEBRUARY 10:15–12:00 Session 4 I Clinical trials and novel therapies Room Adam-von-Trott-Saal Chairs V. Ellenrieder (Göttingen), C. Bruns (Cologne) 10:15 Keynote I Immuno-oncology – the basics and future perspectives H. Flach (Munich) 10:45 In-depth molecular characterisation of pancreatic ductal adenocarcinoma based on patient-derived tumor organoids S. Le Blanc, T. Bauer (Heidelberg), N. Ishaque (Berlin), S. Schuth, A.-K. König M. Volkmar, C.-S. Leonhardt, J. Jabs, U. Toprak, M. Schenk, N. Giese R. Offringa, C. Conrad, M. W. Büchler, M. Schlesner (Heidelberg) R. Eils (Heidelberg, Berlin), O. Strobel (Heidelberg) 10:53 Keynote I Future clinical trial concepts in PDAC J. Siveke (Essen) 11:23 Reliability of determining the resectability of locally progressed pancreatic ductaladenocarcinomas – results from the CONKO-007 multicenter randomised controlled trial (EudraCT:2009-014476-21) U. Wittel (Freiburg), H. Golcher, R. Grützmann (Erlangen) W. Bechstein (Frankfurt), O. Belyaev, W. Uhl (Bochum) M. Ghadimi (Göttingen), U. Hopt (Freiburg), A. Pirkl, D. Lubgan W. Hohenberger (Erlangen), H. Oettle (Friedrichshafen), R. Fietkau (Erlangen) 11:31 Comparative characterisation and epigenetic/metabolic targeting of primary 2D and 3D cultured PDAC cells S.-T. Liffers, S. Mergener, A. Winkelkotte, M. Trajkovic-Arsic, S. S. Lueong J. Forster (Essen), S. Hahn (Bochum), J. Siveke (Essen) 11:39 Keynote l PASS1/2 trial J. Neoptolemos (Heidelberg) 11:47–12:30 Coffee break and visit of the industrial exhibition 12:00–12:15 AG Pankreas Meeting 12:30–14:00 Poster sessions 4–6 (please see pages 22–26) 12:45–13:45 Student meeting Professor Ghadimi 10
WISSENSCHAFTLICHES PROGRAMM I FREITAG, 8. FEBRUAR SCIENTIFIC PROGRAMME I FRIDAY, 8 FEBRUARY 14:00–15:00 Session 5 I Endoscopy Room Adam-von-Trott-Saal Chairs A. Hoffmeister (Leipzig), A. Arlt (Kiel) 14:00 Value of EUS guided drainage in the management of postoperative pancreatic fistulas and fluid collections – a retrospective multi center analysis M. Distler (Dresden), C. Jürgensen (Berlin), A. Arlt (Kiel) S. Brückner (Dresden), M. Ellrichmann (Kiel), K. Matthes (Dresden) M. Ludwig (Berlin), S. Sulk, L. Romberg, S. Zeissig (Dresden) C. Schafmayer, S. Hinz (Kiel), T. Welsch (Dresden), M. Bahra (Berlin) H. Aselmann (Kiel), J. Weitz (Dresden), F. Klein (Berlin), T. Becker (Kiel) J. Hampe (Dresden) 14:08 Endoscopic necrectomy of the infected WON – development of an effective therapy algorithm on the basis of a monocentric population K. Jäger, F. Füldner (Gera), F. Meyer (Magdeburg), U. Will (Gera) 14:16 Keynote l Current standards and controversies in the endoscopic treatment of pancreatic necroses J. Hampe (Dresden) 14:34 Comparative characterisation of postoperative pancreatic fistula according to the 2005 and 2016 definitions of the International Study Group for Pancreatic Surgery E. Petrova, L. Bolm, H. Lapshyn, C. Busch, L. Frohneberg, S. Deichmann K. C. Honselmann, D. Bausch, T. Keck, U. Wellner (Lübeck) 14:42 Keynote l EUS – Interventionen bei benignen und malignen Erkrankungen des Pankreas – Möglichkeiten und Grenzen U. Will (Gera) 14:51–15:15 Coffee break and visit of the industrial exhibition 11
WISSENSCHAFTLICHES PROGRAMM I FREITAG, 8. FEBRUAR SCIENTIFIC PROGRAMME I FRIDAY, 8 FEBRUARY 15:15–17:00 Session 6 I Pancreatic cancer – clinical and translational research Room Adam-von-Trott-Saal Chairs M. Ghadimi (Göttingen), R. Schmid (Munich) 15:15 Keynote l Medical therapy of pancreatic ductal adenocarcinomas A. König (Göttingen) Oxford discussion l surgery for oligo-metastatic pancreatic cancer patients 15:36 1. Opening statement pro vs. contra surgery for oligometastatic PDAC 5min for each speaker 2. Question time for both chairs – 3min for each speaker 3. Exchange of questions between the speakers (3–5min) 4. Question time for the audience (max 5min) 5. Final statements from the speakers – 2min for each speaker 6. Audience vote S. Kersting (Erlangen), T. Seufferlein (Ulm) 16:06 The role of GSK3β in chromatin plasticity and DNA damage repair mechanisms G. E. Schmidt, K. Reutlinger, L. Augustin, M. C. Hasselluhn, A. Tirilomi E. Hessmann, S. A. Johnsen, V. Ellenrieder (Göttingen) 16:14 The interaction of tumor and stroma via the IL-17B/RB axis affects metastatic potential of pancreatic ductal adenocarcinoma J. Li, Q. Sun, J. Zhao, Z. Wang, J. Qin, X. Wu, C. Bruns, Yu. Zhao F. Popp (Cologne) 16:22 The clinical relevance of a novel matrisome signature in PDAC K. C. Honselmann (Lübeck; Boston, MA/US), Dan. Birnbaum (Marseille/FR) S. Begg, P. Finetti, Dav. Birnbaum, F. Bertucci, D. Ting, E. Tai, C. Monsalve M. Mino- Kenudson, K. Lillemoe, C. Fernandez-del Castillo, A. Warshaw A. Liss (Boston, MA/US) 16:30 Identification of superior combinatorial PDA therapies involving cytostatic agents and immunostimulatory antibodies in a clinically relevant mouse model D. Baumann, J. Mochayedi, T. Hägele, J. Drebant, C. Vent, I. Poschke M. Volkmar, R. Offringa (Heidelberg) 16:38 Tumor exosomes modulate progression of PDAC and distant metastasis S. Polaschek, T. Eiseler, T. Seufferlein (Ulm) 12
WISSENSCHAFTLICHES PROGRAMM I FREITAG, 8. FEBRUAR SCIENTIFIC PROGRAMME I FRIDAY, 8 FEBRUARY 16:46 Utilising patient-derived organoids from endoscopic fine needle aspiration as a diagnostic tool and research platform for personalised medicine in pancreatic ductal adenocarcinoma Z. Dantes, H.-Y. Yen, K. Steiger, A. Muckenhuber, N. Pfarr, C. Winter T. Engleitner, S. Lange, R. Öllinger, I. Heid, K. Shi, K. Peschke, K. Feldmann C. Lubeseder-Martellato, M. Martignoni, G. O. Ceyhan, H. Friess, A. Herner L. Liotta, M. Treiber, G. von Figura, M. Abdelhafez, P. Klare C. Schlag (Munich), J. Siveke (Essen), R. Braren, W. Weichert, D. Saur R. Schmid, R. Rad, G. Schneider, M. Reichert (Munich) 16:54–17:15 Coffee break and visit of the industrial exhibition 17:15–18:30 Session 7 I Acute and chronic pancreatitis Room Adam-von-Trott-Saal Chairs J. Rosendahl (Halle a. d. Saale), J. Mayerle (Munich) 17:15 Myeloid derived suppressor cell (MDSCs) differentiation during acute pancreatitis regulates the systemic immune response A. Wilden, J. Glaubitz, J. Golchert, G. Homuth, F. U. Weiß (Greifswald) J. Mayerle (Munich), M. Sendler, M. M. Lerch (Greifswald) 17:23 Mast cell stabilisers ameliorate pain in experimental chronic pancreatitis S. Klauss, S. Schorn, S. Teller, H. Friess, G. O. Ceyhan, I. E. Demir (Munich) 17:31 Keynote I Pancreatitis in patients with lipid disorders M. M. Lerch (Greifswald) 18:01 Gender-dependent mechanisms of autophagy in the transition of acute to chronic pancreatitis K. Diakopoulos, A. Berninger, M. Kowalska, K. Görgülü, M. Lesina, J. Ai A.-F. Karpathaki, D. Kabacaoglu, K. J. Ciecielski, E. Kaya-Aksoy, R. Schmid H. Algül (Munich) 18:09 Pancreatic autophagy attenuates endotoxin-induced pancreatic injury L. Xia, T. Hackert, F. Fortunato (Heidelberg) 18:17 Absence of LMP7 immunoproteasome subunit leads to delayed organ recovery after acute pancreatitis L. De Freitas Chama, F. U. Weiß, F. Ebstein, E. Krüger, M. M. Lerch M. Sendler (Greifswald) 18:30–19:30 General assembly Room Adam-von-Trott-Saal 20:00 Conference dinner and award ceremony at the Freizeit In Hotel (please see page 27) 13
WISSENSCHAFTLICHES PROGRAMM I SAMSTAG, 9. FEBRUAR SCIENTIFIC PROGRAMME I SATURDAY, 9 FEBRUARY 08:30–09:45 Session 8 I Neuroendocrine tumors Room Adam-von-Trott-Saal Chairs J. Werner (Munich), S. Krug (Halle a. d. Saale) 08:30 C-reactive protein (CRP) is associated with poor prognosis by promoting growth signaling pathway activation in pancreatic neuroendocrine neo plasms S. Schimmack, Y. Yang, F. Bergmann, K. Felix, T. Hackert O. Strobel (Heidelberg) 08:38 Cause of death in patients with pancreatic neuroendocrine neoplasms (pNEN) – analysis of 6465 cases in the surveillance, epidemiology, and end results (SEER) database L. P. Breitling, A. Rinke, T. Gress (Marburg) 08:46 Keynote I New German S2K guideline for neuroendocrine tumours: „What is new for PNENs?” T. Gress (Marburg) 09:04 Primary pancreatic tumor resection results in superior overall and prolonged progression free survival after peptide receptor radionuclide therapy in advanced neuroendocrine neoplasms D. Kämmerer (Bad Berka), M. Twrznik (Mühlhausen), D. Hörsch R. P. Baum, M. Hommann (Bad Berka) 09:12 Keynote l Surgery for pancreatic neuroendocrine tumors – which operation for which patient O. Strobel (Heidelberg) 09:30 Mir-132 controls beta cell proliferation and survival in mouse model through the PTEN/AKT/FOXO3 signaling S. Kersting (Erlangen), H. Mziaut (Dresden), M. Solimena (Erlangen, Dresden) 09:38 Pathology has the last word – pancreatic fibrosis is a better parameter for prediction of pancreatic fistula than texture – a retrospective analysis from the RECOPANC Trial E. Petrova (Lübeck), S. Timme, M. Werner (Freiburg), T. Keck (Lübeck) P. Bronsert (Freiburg), U. Wellner (Lübeck) 09:46–10:00 Coffee break and visit of the industrial exhibition 14
WISSENSCHAFTLICHES PROGRAMM I SAMSTAG, 9. FEBRUAR SCIENTIFIC PROGRAMME I SATURDAY, 9 FEBRUARY 10:00–11:45 Session 9 l Tumor microenvironment, stem cells and epigenetics Room Adam-von-Trott-Saal Chairs I. Regel (Munich), E. Hessmann (Göttingen) 10:00 Keynote I Pancreatic cancer D. Tuveson (Cold Spring Harborg, NY/US) 10:30 Immune infiltration patterns in genetically engineered mouse models of pancreatic cancer largely depend on the age and only partly reflect the human disease O. Safak, I. E. Demir, S. Wang, I. Gürcinar, B. Yilmaz, C. Mota-Reyes, H. Friess G. O. Ceyhan (Munich) 10:38 Characterisation of p53-dependent oncogenic EZH2-activity in pancreatic cancer L. Versemann, H. Witte, W. Kopp, J. Spitalieri, X. Xu, V. Ellenrieder E. Hessmann (Göttingen) 10:46 Bulk and single-cell T-cell receptor and transcriptome profiling reveals significant phenotypic, spatial and temporal heterogeneity in the tumor-infiltrating lymphocyte repertoire of pancreatic cancer and melanoma patients I. Poschke, C. L. Tan, I. Heras-Murillo, K. Lindner, A. Rodrizuez-Ehrenfried L. Appel, K. König, M. W. Büchler (Heidelberg), U. Sahin (Mainz), J. Hassel O. Strobel (Heidelberg), M. Flossdorf (Munich), R. Offringa (Heidelberg) 10:54 Keynote I Stem cells and their application in pancreatic cancer research A. Kleger (Ulm) 11:12 Site-specific angiogenesis may promote isolated pulmonary metastasis in pancreatic cancer T. Krauss, S. Teller, H. Friess, G. O. Ceyhan, I. E. Demir (Munich) 11:20 Analysing molecular regulation in pancreatic cancer based on (i) the interaction of tumour and its peritumoral tissue, (ii) intercellular communication within the tumour microenvironment and (iii) intracellular methylation changes in tumour-relevant gene promoters J. D. Hoheisel, M. S. S. Alhamdani (Heidelberg), E. A. Moskalev (Erlangen) A. S. Bauer, Ye. Wu, N. Giese, T. Hackert, O. Strobel M. W. Büchler (Heidelberg) 11:28 Identification of DNA mutations in pancreatic stellate cells V. Böker, J. Kleeff (Halle a. d. Saale) 15
WISSENSCHAFTLICHES PROGRAMM I SAMSTAG, 9. FEBRUAR SCIENTIFIC PROGRAMME I SATURDAY, 9 FEBRUARY 12:00–13:30 Session 10 I Cystic lesions and precursor lesions of the pancreas Room Adam-von-Trott-Saal Chairs I. Esposito (Düsseldorf), D. Bausch (Lübeck) 12:00 A coherent roadmap to generate pancreatic duct-like cells from human pluripotent stem cells to model plasticity and dysplasia in the pancreas M. Hohwieler, M. Breunig, J. Merkle, S. Heller, T. Seufferlein, P.-O. Frappart A. Kleger (Ulm) 12:08 mTORC1 and mTORC2 converge at the Arp 2/3 complex-mediated actin cytoskeleton regulation in promoting ADM formation Ya. Zhao, V. Tissen, L. Chang, J. G. D’Haese, S. Raulefs, J. Qin, J. Akkan, Y. Yu Z. Zhang, J. Cao, S. Benitz, G. O. Ceyhan, H. Friess, B. Kong (Munich) 12:24 Keynote I Cystic lesions of the pancreas – clinical impact and molecular insights P. Michl (Halle a. d. Saale) 12:16 Sensitive and specific identification of mutanome-encoded T-cell epitopes in PDAC on the basis of xenograft NGS data using a hybrid reference genome M. Volkmar (Heidelberg), D. Hoser (Berlin), C. Lauenstein, J. Rebmann A. Hotz-Wagenblatt, J. Rieger, I. Poschke, M. Sprick, A. Trumpp M. Büchler, O. Strobel (Heidelberg), G. Willimsky (Berlin) R. Offringa (Heidelberg) 12:42 Ablation of Hnf1b in adult pancreatic acinar cells inhibits precancerous lesions in mice S. Zhong, A. Hidalgo Sastre, G. von Figura (Munich) 12:50 Functional and mechanistic implications of ARID1A-deficiency in pancreatic metaplasia and PDAC initiation Z. Zhang, W. Kopp, H. Bohnenberger, Xin. Wang, F. Hamdan, M. Sen L. Aperdannier, S. A. Johnsen, E. Hessmann (Göttingen) 12:58 Effects of RSK3 modulation on autophagy and metabolism in pancreatic cancer B. B. K. Dinh, J. Riedel, H. Griesmann, P. Michl (Halle a. d. Saale) 13:06 Keynote I Pancreatic cyst surgery – Oncological, parenchyma sparing, minimally invasive? T. Hackert (Heidelberg) 13:30–14:00 Farewell and invitation to Halle Room Adam-von-Trott-Saal C. Michalski, S. Krug (Halle a. d. Saale) 16
POSTERSPRÄSENTATIONEN I DONNERSTAG, 7. FEBRUAR POSTER SESSIONS I THURSDAY, 7. FEBRUARY 15:45–17:15 Poster session 1 I Tumor biology and therapy Room Terminal 1 Chairs L. Perkhofer (Ulm), R. Schulz-Heddergott (Göttingen) P 01 Crosstalk between IGF2BP RNA-binding proteins and epigenetic regulators in pancreatic neuroendocrine tumors F. Sperling, L. Nietfeld, S. Hüttelmaier, P. Michl, H. Griesmann (Halle a. d. Saale) P 02 Role of PAI-1 in cell-proliferation and metastasis of pancreatic carcinoma cells Q. Wang, A. Rech, F. Seyfried, E. Birgin, F. Rückert, P. Pallavi (Mannheim) P 03 Evaluation of the effect of cancer-associated fibroblasts on the response of pancreatic cancer organoids to drug treatment in a 3D coculture model S. Schuth, S. Le Blanc, J. Jabs, M. Schenk, N. Giese, R. Offringa, C. Conrad O. Strobel (Heidelberg) P 04 Pancreatic cancer cells access nerves via TGFbeta1-mediated transdifferentiation of perineural epithelial cells into mesenchymal-like cells I. E. Demir, U. Bourquain, S. Teller, E. Krohmer, D. Saur, H. Friess G. O. Ceyhan (Munich) P 05 Vitamin D modulates proliferation, migration and activation of pancreatic stellate cells and tumor-stroma crosstalk Ya. Wu, Qu. Li, M. Weniger, M. Ilmer, J. Werner, A. V. Bazhin J. G. D’Haese (Munich) P 06 Intratumoral T cell dysfunction in a murine model of pancreatic cancer E. Nasiri, A. Hanlon, V. Lutz, E. Landmann, M. Huber, M. Buchholz, T. Gress C. Bauer (Marburg) P 07 Immune regulation properties of sulforaphane in pancreatic cancer Y. Wang, A. Wieland, E. Petrikova, J. Gladkich, W. Groß, N. Gretz, I. Herr S. Karakhanova (Heidelberg) P 09 Glyoxalase-I – A novel target for pancreatic cancer? M. Hollenbach, J. Lorenz, I. Sommerer, S. Sonnenberg, P. Reichwald J. Mössner (Leipzig), J. Rosendahl, P. Michl (Halle a. d. Saale) A. Hoffmeister (Leipzig) 17
POSTERSPRÄSENTATIONEN I DONNERSTAG, 7. FEBRUAR POSTER SESSIONS I THURSDAY, 7. FEBRUARY P 10 An immunohistochemical analysis of heat shock protein 27 in pancreatic ductal adenocarcinoma R. Drexler, K.-J. Oldhafer, K.-C. Wagner, M. Küchler (Hamburg) P 12 The serine/threonine kinase FASTK is overexpressed in pancreatic ductal adenocarcinoma and its downregulation inhibits growth in 2D and 3D cell models M. Tatura, T. Gress, M. Buchholz (Marburg) P 13 Characterising inflammatory signaling pathways in ARID1a-deficient PDAC subtypes L. Aperdannier, E. Hessmann (Göttingen) 15:45–17:15 Poster session 2 I Surgery Room Terminal 2 Chairs J. G. D’Haese (Munich), U. Wellner (Lübeck) P 14 Preoperative biliary stenting is associated with higher postoperative morbidity and equivalent mortality in patients with hyperbilirubinemia: an analysis of the German DGAV StuDoQlPancreas registry L. Bolm, E. Petrova, L. Woehrmann (Lübeck), J. Werner (Munich) W. Uhl (Bochum), N. Nuessler (Munich), M. Ghadimi (Göttingen) D. Bausch, H. Lapshyn (Lübeck), J. Gaedcke (Göttingen) O. Belyaev (Bochum), J. G. D‘Haese, T. Klier (Munich), T. Keck U. Wellner (Lübeck) P 15 Metastatic renal cell carcinomas target the fatty pancreas T. Fahlbusch, W. Uhl, C. Braumann (Bochum) P 16 Natural history and treatment of solid-pseudopapillary tumors of the pancreas – a population based study of 100 patients and review of the literature M. Renz (Nuremberg) P 17 Human tissue related kallikreins as potential biomarker and prognostic variable in pancreatic cancer J. Eberhard (Mannheim), A. Soosaipillai (Toronto/CA) C. Reissfelder (Mannheim), E. P. Diamandis (Toronto/CA) F. Rückert (Mannheim) 18
POSTERSPRÄSENTATIONEN I DONNERSTAG, 7. FEBRUAR POSTER SESSIONS I THURSDAY, 7. FEBRUARY P 18 Drainage management in patients receiving pancreatic head resection: a single center analysis in the wake of the PANDRA trial E. Rasbach, C. Reissfelder, F. Rückert (Mannheim) P 19 The presence of special bacteria at the time of surgery seems to increase the rate of postoperative complications after pancreas surgery E. A. Biesel, P. Weyhmüller, O. Sick, F. Makowiec, U. Hopt, S. Fichtner-Feigl U. Wittel (Freiburg) P 20 Alternative approach using CT-guided percutaneous injection of thrombin foam in recurrent bleeding into a pseudocyst due to acute pancreatitis and simultaneous aortic dissectio C. Wex (Magdeburg), J. Jürgens (Hamburg), J. Schiefer (Magdeburg) O. Dudeck (Zurich/CH), J. Rabczak, F. Meyer (Magdeburg) P 21 Prognostic factors of survival in 196 patients undergoing duodeno-pancreatectomy for distal bile duct cancer C. Tjaden, U. Klaiber, U. Hinz, O. Strobel, J. Neoptolemos, M. W. Büchler T. Hackert (Heidelberg) P 22 Inflammatory myofibroblastic tumor of the pancreas – case report and a review of the literature M. Sorleto, S. Elhabash, M. Alnabki, I. Dimopoulus, R. Sekhri, C. Gartung B. Gerdes (Minden) P 23 Delayed gastric emptying does not influence cancer specific survival after pancreatoduodenectomy for pancreatic adenocarcinoma T. R. Glowka, J. Hafke, S. Manekeller, J. C. Kalff (Bonn) P 24 Clinical presentation and outcome of adenosquamous carcinoma of the pancreas – a matched pair analysis to pancreatic ductal adenocarcinoma J. Kaiser, U. Hinz, T. Hank, W. Niesen, D. Jäger, T. Hackert, M. W. Büchler O. Strobel (Heidelberg) P 48 Ezh2 controls PDAC plasticity by regulating differentiation genes S. Patil, Z. Najafova, V. Kari, B. Steuber, H. Bohnenberger, W. Kopp A. Neesse, V. Ellenrieder, S. A. Johnsen, E. Hessmann (Göttingen) 19
POSTERSPRÄSENTATIONEN I DONNERSTAG, 7. FEBRUAR POSTER SESSIONS I THURSDAY, 7. FEBRUARY 15:45–17:15 Poster session 3 I Inflammation and carcinogenesis Room Terminal 3 Chairs G. Beyer (Munich), S. K. Singh (Göttingen) P 26 The role of IL-18 in pancreatic fibrosis Z. Li, M. Weniger, J. Werner, A. V. Bazhin, J. G. D’Haese (Munich) P 27 Autoimmune pancreatitis type 1 associated with a pancreatic pseudocyst F. Hesse, R. Braren, R. Schmid, V. Philipp (Munich) P 28 Regulation of transcription factors in the ER stress recognition system during acute pancreatits R. Bolsmann, F. U. Weiß (Greifswald), J. Mayerle (Munich), M. M. Lerch M. Sendler (Greifswald) P 29 IRAK-M regulates local and systemic immune responses in acute pancreatitis F. Thiel, F. U. Weiß, M. M. Lerch, M. Sendler (Greifswald) P 30 An in vitro system to evaluate potential therapeutic substances for ER stress reduction during pancreatitis J. M. Modenbach, F. U. Weiß (Greifswald), M. Gronbach, C. Oppermann F. El-Hage, J. Pospech (Rostock), M. M. Lerch, M. Sendler (Greifswald) P 31 The influence of receptors for advanced glycation end products (AGE-R´s) and advanced glycation end products (AGE”s) in patients suffering from chronic pancreatitis N. Hesselbarth, R. Böhme, C. Böhme, P. Michl, J. Rosendahl (Halle a. d. Saale) P 32 Role of receptors for advanced glycation end products in development of pancreatitis and pancreatic cancer R. Böhme, N. Hesselbarth, P. Michl, J. Rosendahl (Halle a. d. Saale) P 33 Betacellulin protective effects against experimental acute pancreatitis are ERBB4-dependent K. Hedegger, H. Algül, M. Lesina, M. Schneider, M. Dahlhoff (Munich) P 34 TLR3 is required for pancreatic regeneration A. Hidalgo Sastre, L. Jochheim, K. Steiger, R. Schmid, B. Holzmann G. von Figura (Munich) 20
POSTERSPRÄSENTATIONEN I DONNERSTAG, 7. FEBRUAR POSTER SESSIONS I THURSDAY, 7. FEBRUARY P 35 Efficacy and safety of lumen-apposing metal stents for the drainage of pancreatic fluid collections in a large retrospective multicenter analysis S. Zeissig, S. Sulk, S. Brückner, R. Schmelz, J. Babatz, M. Berning, C. Kirsch S. Pannach, K. Matthes, M. Hohmann (Dresden), S. Reichel (Gera) M. Ellrichmann, A. Arlt (Kiel), U. Will (Gera), J. Hampe (Dresden) P 36 Different characteristics of dibutyltin dichloride-induced chronic pancreatitis and hepatitis in mouse and rat F. Lütt, H. Nizze, R. Jaster (Rostock) P 37 Hippo regulates proliferation and matrix protein synthesis of pancreatic stellate cells L. Spanehl, R. Jaster (Rostock) P 38 Intrapancreatic zymogen activation in response to autophagy modulation in caerulein hyperstimulated mice T. Wartmann, H. Faber-Zuschratter, F. Meyer (Magdeburg), K. Diakopoulos H. Algül, J. Mayerle (Munich), M. M. Lerch (Greifswald), W. Halangk R. Croner (Magdeburg) www.conventus.de © Nejron Photo / Fotolia Success through versatile solutions As a full-service PCO, we provide you with intelligent and innovative solutions in an advisory and implementing manner. 21
POSTERSPRÄSENTATIONEN I FREITAG, 8. FEBRUAR POSTER SESSIONS I FRIDAY, 8. FEBRUARY 12:30–14:00 Poster session 4 I Molecular mechanisms and novel therapies in PDAC Room Terminal 1 Chairs M. Sendler (Greifswald), H. Griesmann (Halle a. d. Saale) P 39 The role of BRD3 in pancreatic ductal adenocarcinoma A. P. Kutschat, F. Hamdan, Xin. Wang, S. A. Johnsen (Göttingen) P 40 Cellular immunotherapy for pancreatic cancer – evaluation of novel target candidates D. Schäfer (Bergisch Gladbach, Göttingen), L. N. Küster, S. Tomiuk A. Bosio (Bergisch Gladbach), J. Missbach-Güntner, D. Pinkert-Leetsch F. Alves (Göttingen), O. Hardt (Bergisch Gladbach) P 41 Impact of Tlr3 on acinar-to-ductal metaplasia and pancreatic cancer progression S. Benitz, L. Fahr, J. Mutter, H. Lisiecki (Munich), J. Kleeff (Halle a. d. Saale) I. Esposito (Düsseldorf), J. Mayerle (Munich), C. Michalski (Halle a. d. Saale) I. Regel (Munich) P 42 Uncovering the role of ERBB receptors in pancreatic ductal adenocarcinoma upon betacellulin-induced signaling in mice K. Hedegger, H. Algül, M. Lesina, M. Schneider, M. Dahlhoff (Munich) P 43 Sulforaphane enhances gemcitabine cytotoxicity in pancreatic cancer through downregulation of miR-30a-3p C. Georgikou, L. Yin, J. Gladkich, X. Xiao (Heidelberg), C. Sticht C. De La Torre (Mannheim), W. Groß (Heidelberg), N. Gretz (Mannheim) S. Karakhanova, I. Herr (Heidelberg) P 44 Metabolic profiling and targeting of pancreatic ductal adenocarcinoma S. Karakaya, A. Winkelkotte, S.-T. Liffers, S. S. Lueong (Heidelberg, Essen) M. Matzka, M. Aichler, A. Walch (Munich), W. Yang, A. Harms T. Hankemeier (Leiden/NL), S. Hahn (Bochum) M. Trajkovic-Arsic J. Siveke (Essen, Heidelberg) P 45 Generation and development of a novel dual bet/hdac inhibitor with promising anti-tumor properties X. Zhang, T. Zegar (Essen), R. Lucas, T. Weiser (Frankfurt) M. Trajkovic-Arsic (Essen), M. Remke (Düsseldorf), S. Mergener (Essen) S. Knapp (Frankfurt), J. Siveke (Essen) 22
POSTERSPRÄSENTATIONEN I FREITAG, 8. FEBRUAR POSTER SESSIONS I FRIDAY, 8. FEBRUARY P 46 Characterisation of immune-based mechanisms in pancreatic ductal adeno carcinoma C. Neander, M. Trajkovic-Arsic, S.-T. Liffers, P. F.-Y. Cheung, J. Siveke (Essen) P 47 Combined treatment with cisplatin and HSP90 Inhibitors – towards a syngeneic orthotopic mouse model of pancreatic cancer therapy K. M. Ewers, S. Patil, W. Kopp, E. Hessmann, M. Dobbelstein (Göttingen) P 25 Investigating the role of SMAD7 in PDAC I. L. Zawallich, Y. Sunami, C. Michalski, J. Kleeff (Halle a. d. Saale) P 49 Boolean network-based modeling of gene regulatory networks mediating the growth-promoting role of CFL1 in pancreatic cancer S. Kühlwein (Ulm), T. Gress (Marburg), H. A. Kestler, M. Buchholz (Ulm) P 50 sgRNA-transgenic mice enable inducible intra-pancreatic genome editing and the generation of large homozygous chromosomal deletions in vivo A. Mishra, K. wolff, Z. Erlangga, M. Manns, A. Vogel, A. Saborowski M. Saborowski (Hannover) 12:30–14:00 Poster session 5 I Surgery Room Terminal 2 Chairs F. Rückert (Mannheim), S. Chikhladze (Freiburg) P 51 Perioperative detection of deeply located pancreatic tumour lesions in mice using optoacoustic and fluorescence-based imaging J. Napp (Göttingen), M. A. Stammes (Enschede, Leiden/NL) J. Claussen (Munich), H. A. J. M. Prevoo, C. F. M. Sier (Gouda/NL) F. J. M. Hoeben (Eindhoven/NL), M. S. Robillard (Nijmegen/NL) A. L. Vahrmeijer (Leiden/NL), T. Devling (Munich) A. B. Chan (Enschede/NL), L.-F. de Geus-Oei (Leiden, Enschede/NL) F. Alves (Göttingen) P 52 Accuracy of CA19-9 in detecting recurrence of pancreatic cancer after curative intended therapy A. Azizian, F. Rühlmann, T. Krause, M. Bernhardt, P. Jo, A. König (Göttingen) M. Kleiß (Kassel), X. Schulz, M. Ghadimi, J. Gaedcke (Göttingen) P 53 Ultrasound imaging – method of choice in early detection of pancreatic carcinoma M. Lang, C. Tjaden, T. Hackert (Heidelberg) 23
POSTERSPRÄSENTATIONEN I FREITAG, 8. FEBRUAR POSTER SESSIONS I FRIDAY, 8. FEBRUARY P 54 Randomised controlled trial of pylorus-preserving versus pylorus-resecting pancreatoduodenectomy (PROPP study) – long-term morbidity and quality of life U. Klaiber, P. Probst, F. J. Hüttner, O. Strobel, M. K. Diener, A. L. Mihaljevic M. W. Büchler, T. Hackert (Heidelberg) P 55 Evaluation of postoperative quality of life after pancreatic surgery and its influencing factors S. Manschikow, S. Deichmann, U. Wellner, K. C. Honselmann, L. Bolm L. Frohneberg, T. Keck, D. Bausch (Lübeck) P 56 Damage control at abdominal trauma – pancreatic injuries M. Putzbach, S. Fabig, N. Weigert, J. Kleeff (Halle a. d. Saale) P 57 Vein resection during pancreatectomy for pancreatic cancer: a meta-analysis Xia. Wang, I. E. Demir, S. Schorn, H. Friess, G. O. Ceyhan (Munich) P 58 Bacterobilia does not influence delayed gastric emptying following pancreatoduodenectomy J. Hafke, S. Manekeller, J. C. Kalff, T. R. Glowka (Bonn) P 59 Incidence and management of surgical revision requiring pancreatic fistulas grade C after pancreaticoduodenectomy – a retrospective analysis of 722 patients A. M. Luu, T. Herzog, L. Krasemann, W. Uhl, C. Braumann (Bochum) P 60 Effects of standardised plant extracts of the japanese Kampo medicine on human and murine pancreatic cancer cells K. Weimer, L. Frank (Göttingen), H. Rausch (Neu-Ulm), V. Ellenrieder S. Cameron (Göttingen) P 61 Incidence and treatment of portal vein thromboses after portal vein resections in pancreatic surgery M. Weniger (Munich), Z. Lu (Nanjing/CN), A. Doll (Munich) Y. Miao (Nanjing/CN), J. Werner, J. G. D’Haese (Munich) P 62 Expression of EWS/FLI-1 oncogene in pancreatic acinar cells induces adipo-cyte replacement Y. Sunami (Halle a. d. Saale), I. Regel, B. Kong, S. Raulefs (Munich) C. Michalski, J. Kleeff (Halle a. d. Saale) 24
POSTERSPRÄSENTATIONEN I FREITAG, 8. FEBRUAR POSTER SESSIONS I FRIDAY, 8. FEBRUARY 12:30–14:00 Poster session 6 I Tumor microenvironment Terminal 3 Chairs D. Ruess (Freiburg), K. C. Honselmann (Lübeck) P 63 Tumor-subtype dependent transcriptional regulation in pancreatic cancer plasticity and resistance M. Tu, S. Önder, J. M. Güntner, V. Ellenrieder, S. K. Singh (Göttingen) P 64 Exploiting tumor-stroma hedgehog signal transduction heterogeneity R. Singh (Marburg) P 65 Anterior gradient 2 promotes the phenotypic transition from ADM to PanIN by suppressing p53 function Z. Zhang, L. Chang, S. Raulefs, N. Maeritz, Ya. Zhao, G. O. Ceyhan H. Friess (Munich), C. Michalski, J. Kleeff (Halle a. d. Saale) B. Kong (Munich) P 66 NFkB2 Signaling is modulated by oncogenic context in the Carcinogenesis in the Pancreas Z. Hassan, C. Schneeweis, M. Wirth, S. Müller, R. Rad, D. Saur, R. Schmid G. Schneider (Munich) P 67 Dexamethasone mediates pancreatic cancer progression by glucocorticoid receptor, TGFb and JNK/AP-1 L. Liu, E. Aleksandrowicz, F. Schönsiegel, N. Bauer, C. C. Nwaeburu, Z. Zhao J. Gladkich, W. Groß, T. Hoppe-Tichy, O. Strobel, I. Herr (Heidelberg) P 68 Comprehensive molecular characterisation of a pancreatic cancer PDX cohort for subtype-specific therapy approaches S.-T. Liffers, S. S. Lueong, S. Mergener, J. Forster (Essen)H. Wolters (Dortmund) R. Viebahn, A. Tannapfel, W. Uhl, S. Hahn (Bochum), J. Siveke (Essen) P 69 Functional characterisation of the Ubiquitin-Proteasome-System in pancreatic ductal adenocarcinoma F. Lang, S. S. Lueong (Essen), O. Karpiuk, F. Bassermann (Munich) J. Siveke (Essen) P 70 STAT3 signaling determines the oncogenic function of NFATc1 in pancreatic cancer plasticity and resistance L. Klein, S. Önder, V. Ellenrieder, S. K. Singh (Göttingen) 25
POSTERSPRÄSENTATIONEN I FREITAG, 8. FEBRUAR POSTER SESSIONS I FRIDAY, 8. FEBRUARY P 71 uPAR knock out induces mesenchymal-epithelial transition (MET) and chemoresistance in AsPC1 cells L. Peng, S. Küffer, V. Venkataramani, J. Kitz, M.-S. Bösherz H. Bohnenberger, F. Fuchs, S. Hakroush, P. Ströbel (Göttingen) P 72 DeltaNp63-dependent super enhancers define molecular identity in pancreatic cancer by an interconnected transcription factor network F. Hamdan, S. A. Johnsen (Göttingen) P 73 Growth inhibitory effects of inhibition of PLAC8 expression in exocrine (PDAC) and neuroendocrine (panNET) tumors of the pancreas is associated with deregulation of a miR-26a-E2F2 axis M. Stark, M. Tatura, A. Kuhl, T. Gress, M. Buchholz (Marburg) P 74 Selective inhibition of sphingolipids metabolism in macrophages using acid sphingomyelinase inhibitor-coupled IL4 receptor specific aptamers Qi. Li, J. Peterhansl, I. Regel, U. M. Mahajan, J. Mayerle (Munich) P 75 Oncogenic NFATc1-activity promotes cancer cachexia in murine PDAC-models D. Spyropoulou, E. Hessmann, H. Bohnenberger, D. Saul (Göttingen) 26
Abend- und Rahmenprogramm Begrüßungsabend im Deutschen Theaterkeller Donnerstag, 7. Februar Mitten im Herzen Göttingens, direkt am Wall, liegt eines der wohl beliebtesten Fotomotive der Stadt: das Deutsche Theater Göttingen. Wir laden Sie recht herzlich zum Begrüßungs- abend in das Bistro ein und freuen uns, mit Ihnen gemeinsam einen gemütlichen Abend bei kleinen Snacks und Getränken zu verbringen. BildPix.de l Fotolia.com Adresse Deutsches Theater Keller + Bistro Theaterplatz 11 Beginn 19:30 Uhr Kosten kostenfrei, eine Anmeldung ist jedoch erforderlich, da die Plätze begrenzt sind Wegbeschreibung Das Deutsches Theater in Göttingen liegt nur 6 Gehminuten von der Alten Mensa Göttingen entfernt. Gehen Sie auf dem Wilhelmsplatz nach Osten und biegen Sie links auf der Burgstraße ab. Nach ca. 100 Metern biegen Sie linkerhand auf die Theaterstraße ab und nach weiteren 200 Metern biegen Sie links ab auf den Theaterplatz, wo Sie das Ziel erreicht haben. Gesellschaftsabend in der Orangerie im Freizeit In Hotel Freitag, 8. Februar Lassen Sie die bisherigen Kongresserlebnisse Revue passieren. Zum Ausklang des zweiten Tages laden wir Sie herzlich in die Orangerie des Hotels Freizeit In ein. Genießen Sie einen unterhaltsamen Abend mit gutem Essen, Musik der Band „Ladies Live“ und Tanz sowie interessanten Gesprächen mit Freunden und Kollegen. Adresse Hotel Freizeit In GmbH Dransfelder Straße 3 Beginn 20:00 Uhr Kosten 45 EUR, eine Anmeldung ist erforderlich, da die Plätze begrenzt sind Wegbeschreibung Nur drei Gehminuten von der Alten Mensa Göttingen entfernt nutzen Sie die Buslinie 61 (Haltestelle „Jüdenstraße“) in Richtung Dransfeld zur Haltestelle „Dransfelder Straße“. Diese liegt dem Hotel Freizeit In direkt gegenüber. 27
INDUSTRIEGESTÜTZE SESSIONS 10:15–12:00 Session 4 I Satellite Symposium supported by Celgene Clinical trials and novel therapies Room Adam-von-Trott-Saal Chairs V. Ellenrieder (Göttingen), C. Bruns (Cologne) 10:15 Keynote I Immuno-Oncology – the basics and future perspectives H. Flach (Munich) 10:45 In-depth molecular characterisation of pancreatic ductal adenocarcinoma based on patient-derived tumor organoids S. Le Blanc, T. Bauer (Heidelberg), N. Ishaque (Berlin), S. Schuth, A.-K. König M. Volkmar, C.-S. Leonhardt, J. Jabs, U. Toprak, M. Schenk, N. Giese R. Offringa, C. Conrad, M. W. Büchler, M. Schlesner (Heidelberg) R. Eils (Heidelberg, Berlin), O. Strobel (Heidelberg) 10:53 Keynote I Future clinical trial concepts in PDAC J. Siveke (Essen) 11:23 Reliability of determining the resectability of locally progressed pancreatic ductaladenocarcinomas – results from the CONKO-007 multicenter randomised controlled trial (EudraCT:2009-014476-21) U. Wittel (Freiburg), H. Golcher, R. Grützmann (Erlangen) W. Bechstein (Frankfurt), O. Belyaev, W. Uhl (Bochum) M. Ghadimi (Göttingen), U. Hopt (Freiburg), A. Pirkl, D. Lubgan W. Hohenberger (Erlangen), H. Oettle (Friedrichshafen) R. Fietkau (Erlangen) 11:31 Comparative characterisation and epigenetic/metabolic targeting of primary 2D and 3D cultured PDAC cells S.-T. Liffers, S. Mergener, A. Winkelkotte, M. Trajkovic-Arsic, S. S. Lueong J. Forster (Essen), S. Hahn (Bochum), J. Siveke (Essen) 11:39 Keynote I PASS1/2 trial J. Neoptolemos (Heidelberg) 28
29 o to lia.c o m i nte r may a l f s p l ay © di
INDUSTRIEGESTÜTZE SESSIONS 17:15–18:30 Session 7 I Satellite Symposium supported by Akcea Acute and chronic pancreatitis Room Adam-von-Trott-Saal Chairs J. Rosendahl (Halle a. d. Saale), J. Mayerle (Munich) 17:15 Myeloid derived suppressor cell (MDSCs) differentiation during acute pancreatitis regulates the systemic immune response A. Wilden, J. Glaubitz, J. Golchert, G. Homuth, F. U. Weiß (Greifswald) J. Mayerle (Munich), M. Sendler, M. M. Lerch (Greifswald) 17:23 Mast cell stabilisers ameliorate pain in experimental chronic pancreatitis S. Klauss, S. Schorn, S. Teller, H. Friess, G. O. Ceyhan, I. E. Demir (Munich) 17:31 Keynote I Pancreatitis in patients with lipid disorders M. M. Lerch (Greifswald) 18:01 Gender-dependent mechanisms of autophagy in the transition of acute to chronic pancreatitis K. Diakopoulos, A. Berninger, M. Kowalska, K. Görgülü, M. Lesina, J. Ai A.-F. Karpathaki, D. Kabacaoglu, K. J. Ciecielski, E. Kaya-Aksoy, R. Schmid H. Algül (Munich) 18:09 Pancreatic autophagy attenuates endotoxin-induced pancreatic injury L. Xia, T. Hackert, F. Fortunato (Heidelberg) 18:17 Absence of LMP7 immunoproteasome subunit leads to delayed organ recovery after acute pancreatitis L. De Freitas Chama, F. U. Weiß, F. Ebstein, E. Krüger, M. M. Lerch M. Sendler (Greifswald) 30
Connecting and Advancing Health Sciences The Interdisciplinary Approach to Gastrointestinal Medicine VISCERAL MEDICINE is your one-stop source for essential knowledge Visceral Breast Care needed to master the major interdisciplinary challenges in gastro- Medicine intestinal medicine and surgery. Each issue focuses on one selec- Gastroenterology, Endoscopy and Surgery – The Interdisciplinary Approach to Gastrointestinal Disease ted topic, and the invited reviews provide a comprehensive, state- of-the-art background in clinical practice and research. A panel of specialists in gastroenterology, surgery, radiology, and pathology discusses different approaches to diagnosis and treatment of the featured topic. Original articles, case reports, and commentaries S. Karger Medical and Scientific Publishers Basel · Freiburg · Paris · London · Associated Organ New York · Chennai · New Delhi · for Continuing Education add additional valuable insights. Bangkok · Beijing · Shanghai · Tokyo · Kuala Lumpur · Singapore · Sydney www.karger.com/vis In cooperation with DGAV (Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie) More than 40 Years of Excellence For over 40 years, ONCOLOGY RESEARCH AND TREATMENT has been an inter- disciplinary forum for cancer research and treatment. Peer-reviewed original and review articles cover a wide range of topics and aspects in medical and hemato-oncology. Focus issues select one specific cutting-edge topic and expand on its various facets in the form of mini reviews. Compact and current, ONCOLOGY RESEARCH AND TREATMENT keeps both clinicians and researchers up-to-date. Österreichische Gesellschaft für Hämatologie & Medizinische Onkologie Österreichische Gesellschaft für Hämatologie & Medizinische Onkologie www.karger.com/ort Official DGHO – Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie Organ of ÖGHO – Österreichische Gesellschaft für Hämatologie und Medizinische Onkologie DFaG – Deutsche Fatigue Gesellschaft AIO – Arbeitsgemeinschaft Internistische Onkologie in der deutschen Krebsgesellschaft e.V. SGH-SSH – Schweizerische Gesellschaft für Hämatologie Member of Deutsche Krebsgesellschaft e.V. S. Karger Verlag für Medizin und Naturwissenschaften GmbH Wilhelmstraße 20A t +49 761 45207- 0 79098 Freiburg f +49 761 45207- 14 www.karger.com information@karger.com 31
SPONSOREN UND MEDIENKOOPERATION Ein großes Dankeschön gilt allen Partnern für ihre Unterstützung und kooperative Zusammenarbeit: Premiumsponsoren Akcea Therapeutics Celgene GmbH Silbersponsoren SERVIER Deutschland GmbH Bronzesponsoren Bristol-Myers Squibb GmbH & Co. KGaA GE Healthcare GmbH Johnson & Johnson Medical GmbH - Ethicon Ipsen Pharma GmbH Weitere Sponsoren Boston Scientific Halozyme, Inc. Lilly Deutschland GmbH MTW-Endoskopie W. Haag KG Peter Pflugbeil GmbH Medienkooperation S. Karger GmbH „Karger Kompass Onkologie“ „Oncology Research and Treatment“ „Visceral Medicine“ Stand bei Drucklegung 32
Successful patient management requires a lot more than one move. AXIOS™ Stent and Electrocautery Enhanced Delivery System Bringing the patient care pieces together. The AXIOS Stent and Delivery System is indicated for use to facilitate transgastric or transduodenal endoscopic drainage of a pancreatic pseudocyst or a walled-off necrosis with ≥ 70% fluid content or the biliary tract. All trademarks are the property of their respective owners. Caution: The law restricts this device to sale by or on the order of a physician. Product available in the European Economic Area (EEA) only. Please check availability with your local sales representative or customer service. Indications, Contraindications, Warnings and Instructions for Use can be found in the product labeling supplied with each device. Contact your local sales representative or visit 33 2016 Copyright © Boston Scientific Corporation or its affiliates. All rights reserved. www.bostonscientifi c.eu/gastroenterology. ENDO-426401-AA
AUSSTELLER Aussteller Standnummer Arbeitskreis der Pankreatektomierten e. V. 9 Akcea Therapeutics 5 BAXTER Deutschland GmbH 12 Bracco Imaging Deutschland GmbH 18 Bristol-Myers Squibb 16 Celgene GmbH 7 Dr. Falk Pharma GmbH 2 Ewimed 11 GE Healthcare GmbH 8 IntraOp 14 Ipsen Pharma GmbH 4 Johnson & Johnson 19 Liquid Biopsy GmbH 21 LISA Laser Products GmbH 1 Meda Pharma 20 Medi-Globe GmbH 10 Medtronic 15 Nordmark Arzneimittel GmbH & Co. KG 6 Novartis Pharma GmbH 13 Roche Pharma AG 17 Servier Deutschland GmbH 3 Stand bei Drucklegung 34
RAUM- UND AUSSTELLERPLAN 16 3 1 5 11 15 21 2 10 14 20 2 9 13 19 8 12 4 18 7 17 3 zum Vortragssaal 6 g an ng i te up Ha ePoster Sta on 1 Catering Check-In Stand bei Drucklegung 35
ALLGEMEINE INFORMATIONEN Allgemeine Geschäftsbedingungen Die Allgemeinen Geschäftsbedingungen entnehmen Sie bitte der Tagungs- AGB homepage. Anwesenheitslisten und Teilnahmezertifikate Für die Zertifizierung werden die Teilnehmer gebeten, sich täglich mit ihrem EFN-Barcode am Check-In einzuscannen. Dort erhalten Sie auch die Teilneh- merzertifikate. Catering Getränke und Snacks werden den Teilnehmern kostenfrei während der Pausen angeboten. Kongresssprache Die Vorträge sowie Posterpräsentationen werden auf Englisch gehalten. Posterausstellung Alle Poster können während der gesamten Tagung sowohl an den ePoster- Terminals als auch an kleinen Bildschirmen zum Selbststudium eingesehen werden. Vortragsannahme Bitte geben Sie Ihren Vortrag direkt im Hörsaal ab. Wissenschaftliche Preise Die Preisverleihungen finden während des Gesellschaftsabends am Freitag statt. Die besten Abstracteinreichungen sind im Programm mit einem Pokal gekennzeichnet. Zertifizierung und Fortbildungspunkte Die 39. Jahrestagung des Deutschen Pankreasclub e. V. wurde von der Ärzte- kammer Niedersachsen mit folgenden Punkten zertifiziert: Donnerstag 3 Punkte Freitag 6 Punkte Samstag 3 Punkte 36
Index Referenten, Autoren und Vorsitzende A Abdelhafez, M. 12 Berninger, A. 13, 30 Acciuffi, S. 7, 9 Bertucci, F. 12 Ai, J. 13, 30 Beyer, G. 20 Aichler, M. 22 Biesel, E. A. 19 Akkan, J. 8, 16 Birgin, E. 17 Aleksandrowicz, E. 25 Birnbaum, Dan. 12 Algül, H. 7, 13, 20, 21, 22, 30 Birnbaum, Dav. 12 Alhamdani, M. S. S. 15 Böhme, C. 20 Alnabki, M. 19 Böhme, R. 20 Alves, F. 22, 23 Bohnenberger, H. 16, 19, 26 Aperdannier, L. 16, 18 Böker, V. 15 Appel, L. 15 Bolm, L. 9, 11, 18, 24 Arlt, A. 6, 11, 21 Bolsmann, R. 20 Arnold, F. 7 Bösherz, M.-S. 26 Aselmann, H. 11 Bosio, A. 22 Augustin, L. 12 Bourquain, U. 17 Azizian, A. 23 Braren, R. 12, 20 Braumann, C. 18, 24 B Breitling, L. P. 14 Babatz, J. 21 Breunig, M. 8, 16 Bahra, M. 11 Bronsert, P. 14 Bassermann, F. 25 Brooks, J. 9 Bauer, A. S. 15 Brückner, S. 11, 21 Bauer, C. 17 Bruns, C. 10, 12, 28 Bauer, N. 25 Buchholz, M. 17, 18, 23, 26 Bauer, T. 10, 28 Buchler, M. 9 Baum, R. P. 14 Büchler, M. W. 7, 9, 10, 15, 19, 24, 28 Baumann, D. 12 Büchter, M. 8 Bausch, D. 9, 11, 16, 18, 24 Busch, C. 11 Bazhin, A. V. 7, 17, 20 Bechstein, W. 10, 28 C Becker, T. 11 Cameron, S. 24 Begg, S. 12 Cao, J. 8, 16 Belyaev, O. 10, 18, 28 Ceyhan, G. O. 8, 9, 12, 13, 15, 16, 17, 24 Benitz, S. 8, 16, 22 25, 30 Bergmann, F. 14 Chan, A. B. 23 Bernhardt, M. 23 Chang, L. 16, 25 Berning, M. 21 Cheung, P. F.-Y. 23 37
Index Referenten, Autoren und Vorsitzende Chikhladze, S. 23 Ellenrieder, V. 8, 10, 12, 15, 19, 24, 25, 28 Ciecielski, K. J. 13, 30 Ellrichmann, M. 11, 21 Claussen, J. 23 Engleitner, T. 12 Conrad, C. 10, 17, 28 Erlangga, Z. 23 Croner, R. 7, 9, 21 Esposito, I. 16, 22 Ewers, K. M. 23 D D’Haese, J. G. 7, 16, 20, 24 F Dahlhoff, M. 20, 22 Faber-Zuschratter, H. 21 Dantes, Z. 12 Fabig, S. 24 De Freitas Chama, L. 13, 30 Fahlbusch, T. 18 de Geus-Oei, L.-F. 23 Fahr, L. 8, 22 De La Torre, C. 22 Feldmann, K. 12 Deichmann, S. 11, 24 Felix, K. 14 Demir, I. E. 7, 9, 13, 15, 17, 24, 30 Fernandez-del Castillo, C. 12 Devling, T. 23 Fichtner-Feigl, S. 19 D‘Haese, J. G. 7, 8, 16, 17, 18, 20, 24 Fietkau, R. 10, 28 Diakopoulos, K. 13, 21, 30 Finetti, P. 12 Diamandis, E. P. 18 Flach, H. 10, 28 Diener, M. K. 24 Flossdorf, M. 15 Dimopoulus, I. 19 Forster, J. 10, 25, 28 Dinh, B. B. K. 16 Fortunato, F. 13, 30 Distler, M. 9, 11 Frank, L. 24 Dobbelstein, M. 23 Frappart, P.-O. 7, 16 Doll, A. 24 Friess, H. 8, 9, 12, 13, 15, 16, 17, 24, 25, 30 Dralle, H. 9 Frohneberg, L. 11, 24 Drebant, J. 12 Fuchs, F. 26 Drewes, R. 7 Füldner, F. 11 Drexler, R. 18 Dudeck, O. 19 G Gaedcke, J. 6, 9, 18, 23 E Gartung, C. 19 Eberhard, J. 18 Gastinger, I. 9 Ebstein, F. 13, 30 Georgikou, C. 22 Eils, R. 10, 28 Gerdes, B. 19 Eiseler, T. 12 Gerken, G. 8 Elhabash, S. 19 Ghadimi, M. 10, 12, 18, 23, 28 El-Hage, F. 20 Ghaneh, P. 9 38
Sie können auch lesen